U.S. markets closed
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • Dow 30

    33,874.24
    -71.34 (-0.21%)
     
  • Nasdaq

    14,271.73
    +18.46 (+0.13%)
     
  • Russell 2000

    2,303.47
    +7.52 (+0.33%)
     
  • Crude Oil

    73.32
    +0.24 (+0.33%)
     
  • Gold

    1,778.30
    -5.10 (-0.29%)
     
  • Silver

    25.94
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1936
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • GBP/USD

    1.3967
    +0.0019 (+0.14%)
     
  • USD/JPY

    110.9600
    +0.3250 (+0.29%)
     
  • BTC-USD

    33,432.21
    +881.87 (+2.71%)
     
  • CMC Crypto 200

    800.68
    -9.51 (-1.17%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate.

  • This study's objective was to assess neurotoxicity resulting from a long residence time of a local anesthetic in proximity to the sciatic nerve in rabbits.

  • The rabbit limbs dosed with the liposomal prolonged bupivacaine release (Probudur), at ten times more than free bupivacaine, showed no nerve damage signs.

  • Further, nerves injected with Probudur showed mild signs of inflammation and small residues of the hydrogel in granulomas, indicating a long residence time of the hydrogel at the injection site, but no histopathological signs of nerve damage.

  • Price Action: VRPX shares are up 5.26% at $5.1 during the market trading session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.